What Is Synthetic Biology?
Synthetic biology is the engineering discipline that designs, builds, and tests biological systems for useful purposes. By applying engineering principles, standardized genetic parts, and computational design tools to living organisms, synthetic biologists can program cells to produce medicines, food ingredients, materials, fuels, and chemicals that are difficult or impossible to manufacture through traditional chemistry.
The field rests on a stack of enabling technologies: DNA reading (sequencing), DNA writing (synthesis), DNA editing (CRISPR and related tools), computational biology (AI-driven protein and pathway design), and bioprocess engineering (fermentation at industrial scale). The dramatic cost reduction in each of these layers over the past decade, particularly DNA synthesis costs falling from dollars per base pair to fractions of a cent, has made synthetic biology commercially viable across multiple verticals.
Synthetic biology venture funding reached $17.3 billion cumulatively through 2025, though the sector experienced significant public market corrections in 2022 and 2023 following the Ginkgo Bioworks downturn. The industry has since consolidated around companies with demonstrated product-market fit and clear paths to revenue, entering what many observers call the production era of synthetic biology.
Application Verticals
Synthetic biology spans a wide range of industries, each with distinct market dynamics and technology readiness levels.
Therapeutics. Cell and gene therapies, mRNA medicines, and engineered protein therapeutics represent the highest-value application of synthetic biology. The success of mRNA COVID-19 vaccines (Moderna, BioNTech/Pfizer) validated large-scale biological manufacturing and opened massive markets for mRNA-based cancer vaccines, rare disease treatments, and infectious disease prophylaxis. Moderna alone generated over $18 billion in mRNA vaccine revenue in 2022 and is advancing a pipeline of mRNA cancer vaccines and therapeutic programs.
Beyond mRNA, synthetic biology enables engineered T-cell therapies (CAR-T), where patients' immune cells are genetically modified to attack cancer. Companies including Kite (Gilead), Novartis, and Bristol Myers Squibb have commercialized CAR-T therapies, with combined revenue exceeding $5 billion annually. Next-generation approaches use synthetic biology to create off-the-shelf allogeneic cell therapies, gene circuits that make T-cells smarter, and engineered microbes for gut-targeted therapeutics.
Precision fermentation and food. Synthetic biology enables the production of animal-derived proteins, fats, and flavors through engineered microorganisms in fermentation tanks, without animals. Perfect Day produces whey protein through engineered yeast. Impossible Foods uses engineered yeast to produce heme, the molecule that makes its plant-based burgers taste like meat. The Every Company produces egg proteins, and Motif FoodWorks develops functional food ingredients.
The precision fermentation market is projected to grow from approximately $3 billion in 2025 to $35 billion by 2035, driven by cost improvements as fermentation processes scale to commodity pricing. The challenge is achieving cost parity with conventional agriculture, which requires fermentation yields and energy costs that many companies are still working to reach.
Agriculture. Synthetic biology is being applied to crop improvement (beyond traditional GMO approaches), nitrogen fixation (reducing fertilizer dependence), biopesticides, and soil microbiome engineering. Pivot Bio has developed engineered nitrogen-fixing microbes that colonize corn roots and reduce synthetic fertilizer needs by 25% or more. Inari Agriculture uses gene editing for crop trait improvement without introducing foreign DNA. Bayer and Corteva are incorporating synthetic biology tools into their breeding programs.
AI and biology convergence. The intersection of AI and synthetic biology has become one of the most active areas of innovation and investment. Machine learning models now design novel proteins, predict metabolic pathway outputs, optimize fermentation processes, and identify drug targets from genomic data. Companies at this intersection include Absci (generalized AI antibody design), Arzeda (computational enzyme design), Recursion Pharmaceuticals (AI-driven drug discovery using cellular imaging), and Insilico Medicine (AI target identification and drug design).
DeepMind's AlphaFold, which predicts protein structures with near-experimental accuracy, has transformed structural biology and accelerated protein engineering across the industry. AlphaFold's 2024 update expanded to protein-ligand and protein-DNA complex prediction, further enabling rational design of biological systems.
Tools and infrastructure. The synthetic biology tooling layer includes DNA synthesis companies (Twist Bioscience, Ginkgo-owned Gen9, IDT), DNA sequencing platforms (Illumina, Oxford Nanopore, PacBio), CRISPR tool companies (Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Beam Therapeutics), and foundry/automation companies (Ginkgo Bioworks, Strateos, Benchling). Twist Bioscience has become the dominant supplier of synthetic DNA libraries, with revenue growing to over $300 million annually.
The Ginkgo Lesson
Ginkgo Bioworks, the highest-profile synthetic biology platform company, serves as both an instructive case study and a cautionary tale. Ginkgo went public via SPAC in 2021 at a $15 billion valuation, positioning itself as the horizontal platform for cell programming across industries. By 2024, Ginkgo's market capitalization had fallen below $500 million amid questions about revenue quality, customer concentration, and the viability of the platform-royalty business model in biology.
The Ginkgo experience taught the industry several lessons: biological platform value is harder to monetize than software platforms; vertical integration (owning the product, not just the engineering service) often captures more value; and public market investors demand clear revenue trajectories, not optionality narratives. Post-Ginkgo, synthetic biology investment has shifted toward companies with defined products, identified customers, and demonstrated unit economics.
CRISPR Revolution
The CRISPR-Cas9 gene editing system, discovered as a bacterial immune mechanism and adapted for precise genome editing, has transformed synthetic biology since its initial demonstration in 2012. CRISPR enables targeted modification of DNA in living cells with unprecedented ease and precision, replacing earlier gene editing approaches (zinc finger nucleases, TALENs) that were expensive and cumbersome.
The clinical impact arrived definitively in 2023 when the FDA and UK MHRA approved Casgevy (exagamglogene autotemcel), the first CRISPR-based therapy, developed by CRISPR Therapeutics and Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta-thalassemia. Casgevy represents a functional cure for patients with these devastating blood disorders, editing patients' own bone marrow stem cells to produce functional hemoglobin.
Next-generation CRISPR technologies are advancing rapidly. Base editing (developed by David Liu at the Broad Institute, commercialized by Beam Therapeutics) enables precise single-letter DNA changes without cutting the double helix. Prime editing offers search-and-replace genome editing. Epigenetic editing modifies gene expression without changing DNA sequence. Each expansion of the CRISPR toolkit opens new therapeutic and industrial applications.
Precision Fermentation Scale-Up
The central engineering challenge for synthetic biology's food, materials, and chemicals applications is achieving industrial fermentation at scale and cost that compete with conventional production methods.
Current precision fermentation costs range from $5 to $50 per kilogram of protein depending on the organism, product, and facility. Reaching cost parity with conventional dairy protein ($2 to $4/kg) or commodity chemicals requires:
Strain optimization. Engineered organisms must produce target molecules at high titers (grams per liter), rates (grams per liter per hour), and yields (grams per gram of feedstock). Achieving all three simultaneously is the core challenge of metabolic engineering. AI-driven strain design is accelerating this process by predicting genetic modifications that improve all three metrics.
Feedstock flexibility. Most fermentation processes use refined sugars as feedstock, which represents 30% to 60% of production costs. Companies working on cellulosic feedstocks (agricultural waste, forestry residues) or gaseous feedstocks (CO2, methane) could dramatically reduce costs if conversion efficiency improves.
Capital efficiency. Building large-scale fermentation facilities costs $200 million to $500 million. Companies including Culture Biosciences and Synonym are developing contract fermentation capacity to reduce the capital required for individual synthetic biology companies to reach production scale.
Key Companies Beyond Those Mentioned
Genentech/Roche remains the largest biologics manufacturer globally, with deep synthetic biology capabilities applied to antibody and protein drug production.
Amyris (now bankrupt and IP acquired) demonstrated both the promise and peril of synthetic biology commercialization. At its peak, Amyris produced farnesene-derived cosmetic ingredients, fuels, and flavors through engineered yeast fermentation but could not achieve sustainable unit economics at scale.
Solugen produces specialty chemicals through enzyme-catalyzed processes at lower cost and carbon footprint than petrochemical routes. The company has achieved profitability in select product lines, making it a notable example of sustainable synthetic biology economics.
Zymergen (acquired by Ginkgo) and Bolt Threads (wound down spider silk program) represent additional cautionary examples of synthetic biology companies that could not bridge the gap between laboratory demonstration and profitable production.
Mammoth Biosciences and Arbor Biotechnologies are developing next-generation CRISPR systems with improved properties for therapeutic and diagnostic applications.
Frequently Asked Questions
What is synthetic biology?
Synthetic biology is an engineering discipline that designs and builds biological systems for practical applications. By reprogramming the DNA of living cells, synthetic biologists can create organisms that produce medicines, food ingredients, materials, and chemicals. The field combines genetic engineering, computational biology, and bioprocess engineering. Key enabling technologies include CRISPR gene editing, AI-driven protein design, low-cost DNA synthesis, and industrial-scale fermentation.
What are the main applications of synthetic biology?
Major application areas include therapeutics (mRNA medicines, cell and gene therapies, engineered antibodies), food and agriculture (precision fermentation for animal-free proteins, engineered crop traits, nitrogen-fixing microbes), industrial chemicals and materials (bio-based alternatives to petrochemicals), and biological tools (DNA synthesis, sequencing, and editing platforms). The therapeutics segment generates the most revenue today, while food and materials applications are scaling toward commercial viability.
How much funding has synthetic biology received?
Cumulative synthetic biology venture funding reached approximately $17.3 billion through 2025. Annual funding peaked in 2021 at over $6 billion during the biotech bull market, then corrected to $2 billion to $3 billion annually in 2023 and 2024 as public markets repriced platform companies. Funding recovered in 2025 with increased focus on AI-biology convergence companies and late-stage clinical programs. Government funding through the US Biotechnology and Biomanufacturing Initiative and similar programs globally adds billions more.
What is precision fermentation?
Precision fermentation uses genetically engineered microorganisms (yeast, bacteria, or fungi) grown in fermentation tanks to produce specific proteins, fats, flavors, or other molecules traditionally derived from animals or petrochemicals. The organisms are programmed with synthetic DNA sequences that instruct them to manufacture the target molecule, which is then purified from the fermentation broth. This approach can produce identical molecules to those found in nature (such as whey protein or collagen) without animals, at potentially lower environmental cost.
Is CRISPR safe for human use?
The first CRISPR therapy, Casgevy for sickle cell disease, received FDA approval in 2023 after clinical trials demonstrating both safety and efficacy. CRISPR-based therapies undergo the same rigorous regulatory review as any new drug. Known risks include off-target editing (unintended DNA changes at sites similar to the target) and delivery challenges. Ongoing monitoring of treated patients shows durable therapeutic effects without significant adverse events. Multiple additional CRISPR therapies are in clinical trials for cancer, liver diseases, hereditary blindness, and other conditions.